ClinicalTrials.gg
CompletedNCT02974153PROMISE 2Updated Jun 9, 2020Results posted

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

A Phase 3 interventional study of ALD403 (Eptinezumab) and Placebo in Migraine Disorders, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 145 sites in 13 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-09.

Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,121
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
Largest of 21
1,121 · median 193
Started
2016
with 1 other
Phase 3
13 of 21
5 open now
Registered
5th of 21
by date
Lead sponsor
6 of 21
Alder Biopharmaceuticals, Inc.

Among the 21 studies testing eptinezumab in Migraine Disorders, this one has the largest enrollment, is one of 2 that started in 2016, is one of 13 in phase 3, and was the 5th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.

03

Conditions studied

  • Migraine Disorders

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between 18 and 65 years of age, inclusive, who were diagnosed with migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months before screening.
  • During the 28 day screening period, subjects must adequately complete the headache eDiary and must have headaches occurring on ≥ 15 to ≤ 26 days of which at least 8 must be migraine days.
  • Headache eDiary was completed on at least 24 of the 28 days prior to randomization.

Exclusion criteria

Exclusion Criteria:

  • Confounding and pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome).
  • Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. Patients with a lifetime history of psychosis, mania, or dementia are excluded.
  • Any use of botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections within 4 months prior to screening and during the screening period.
  • History or diagnosis of complicated migraine (ICHD-III beta version, 20134), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or sporadic and familial hemiplegic migraine.
  • Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening.
  • Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,121 participants (actual)

Study arms

  • Experimental
    ALD403 (Eptinezumab) Dose Level 1

    ALD403 (Eptinezumab) Dose Level 1 (IV)

    Biological: ALD403 (Eptinezumab)

  • Experimental
    ALD403 (Eptinezumab) Dose Level 2

    ALD403 (Eptinezumab) Dose Level 2 (IV)

    Biological: ALD403 (Eptinezumab)

  • Placebo comparator
    Placebo

    Placebo (IV)

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Monthly Migraine Days

    Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12

    Time frame: Week 1-12

Secondary outcomes

  1. 75% Migraine Responder Rate

    Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.

    Time frame: Week 1-12

  2. 75% Migraine Responder Rate - 4 Week

    Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 4, as compared with baseline.

    Time frame: Week 1-4

  3. 50% Migraine Responder Rate

    Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline.

    Time frame: Week 1-12

  4. Percentage of Participants With a Migraine on the Day After Dosing

    The percentage of participants with a migraine on the day after dosing, where Day 0 is treatment Day and Day 1 is the day after dosing.

    Time frame: Day 1

  5. Change in Monthly Acute Medication Days

    An acute medication migraine day was a day with any triptan or ergotamine use as recorded in the eDiary.

    Time frame: Week 1-12

  6. Change From Baseline of Headache Impact Test (HIT-6) Score

    The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact).

    Time frame: Baseline to Week 12

  7. Change in Migraine Prevalence From Baseline to Week 4

    The avarage change in percentage of participants with a migraine on any given day during baseline and the equivalent avarage rate over Weeks 1-4.

    Time frame: Baseline to Week 4

  8. 75% Headache Responder Rate

    Participants with an average reduction in headache days of at least 75% over Weeks 1 to 12, as compared with baseline.

    Time frame: Week 1-12

  9. 50% Headache Responder Rate

    Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline.

    Time frame: Week 1-12

  10. 100% Migraine Responder Rate

    For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.

    Time frame: Week 1-12

  11. 100% Headache Responder Rate

    For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.

    Time frame: Week 1-12

  12. Change From Baseline in Monthly Migraine Days (Weeks 13-24)

    Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 13-24.

    Time frame: Week 13-24

  13. Change From Baseline in Monthly Headache Days (Weeks 1-12)

    Monthly headache days are summarized in 28-day intervals, and averaged across Weeks 1-12.

    Time frame: Week 1-12

  14. Time to First Migraine After Dosing

    The time to first migraine after dosing based upon the migraine data entered into the eDiary

    Time frame: 32 weeks

  15. Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication

    The percentage of migraines with acute medication usage. Participants with no migraine will be included with a rate of zero.

    Time frame: Week 1-12

  16. Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication

    The percentage of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.

    Time frame: Week 1-12

  17. Percent Change in Frequency of Migraine Days - Week 1-12

    The percent change in frequency of migraine days from Weeks 1-12 was calculated as the number of migraine days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of migraine days over Weeks 1-12.

    Time frame: Week 1-12

  18. Percent Change in Frequency of Headache Days - Week 1-12

    The percent change in frequency of headache days from Weeks 1-12 was calculated as the number of headache days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of headache days over Weeks 1-12.

    Time frame: Week 1-12

  19. Change From Baseline in Percentage of Severe Migraines

    The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12.

    Time frame: Week 1-12

  20. Change From Baseline in Percentage of Severe Headache

    The change from baseline in percentage of headaches that are classified as severe over Weeks 1-12.

    Time frame: Week 1-12

  21. Change From Baseline in Monthly Migraine Hours, Weeks 1-12

    Migraine hours are the sum of migraines within 4 week intervals, and the average 4 week duration within 12 weeks.

    Time frame: Week 1-12

  22. Change From Baseline in Monthly Headache Hours, Weeks 1-12

    Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.

    Time frame: Week 1-12

  23. Duration of Migraine-Free Intervals

    The number of participants with migraine-free intervals starting within the first 2 weeks of treatment. The longest migraine free interval for each participant is recorded.

    Time frame: 32 weeks

  24. Change From Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores

    The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks. All scales are on a range of 0 to 100, with 0 being the worst and 100 being the best. Scales are reported separately. Increases from baseline indicate improvement.

    Time frame: Baseline to Week 12

  25. Patient Global Impression of Change (PGIC) at Week 12

    The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.

    Time frame: Week 12

  26. Health Related Quality of Life (EQ-5D-5L) at Week 12

    The EQ-5D-5L is a descriptive system of health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.

    Time frame: Week 12

07

Results

Posted Jun 9, 2020

Participant flow

Participant flow — Overall Study
Milestone300 mg ALD403100 mg ALD403Placebo
Started374372375
Participants treated350356366
Completed322324325
Not completed524850
Withdrew: Adverse event601
Withdrew: Lack of efficacy6510
Withdrew: Lost to follow-up91017
Withdrew: Physician decision021
Withdrew: Withdrawal by subject91611
Withdrew: Study burden873
Withdrew: Other1487

Outcome measures

PrimaryChange From Baseline in Monthly Migraine Days

Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12

Time frame:
Week 1-12
Reported as:
Mean · Migraine Days
Change From Baseline in Monthly Migraine Days
Migraine Days300 mg ALD403100 mg ALD403Placebo
Change From Baseline in Monthly Migraine Days-8.2 (-23 to 11)-7.7 (-22 to 10)-5.6 (-25 to 9)
Statistical analysis
  • 300 mg ALD403 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -2.60 · 95% CI -3.45 to -1.74
  • 100 mg ALD403 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -2.03 · 95% CI -2.88 to -1.18
Secondary75% Migraine Responder Rate

Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.

Time frame:
Week 1-12
Reported as:
Count of participants · Participants
75% Migraine Responder Rate
Participants300 mg ALD403100 mg ALD403Placebo
75% Migraine Responder Rate1169555
Statistical analysis
  • 300 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Mean difference (final values): 18.1 · 95% CI 12.0 to 24.3
  • 100 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = 0.0001 · Mean difference (final values): 11.7 · 95% CI 5.8 to 17.5
Secondary75% Migraine Responder Rate - 4 Week

Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 4, as compared with baseline.

Time frame:
Week 1-4
Reported as:
Count of participants · Participants
75% Migraine Responder Rate - 4 Week
Participants300 mg ALD403100 mg ALD403Placebo
75% Migraine Responder Rate - 4 Week12911057
Statistical analysis
  • 300 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Mean difference (final values): 21.3 · 95% CI 15.0 to 27.6
  • 100 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Mean difference (final values): 15.3 · 95% CI 9.3 to 21.4
Secondary50% Migraine Responder Rate

Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline.

Time frame:
Week 1-12
Reported as:
Count of participants · Participants
50% Migraine Responder Rate
Participants300 mg ALD403100 mg ALD403Placebo
50% Migraine Responder Rate215205144
Statistical analysis
  • 300 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Mean difference (final values): 22.1 · 95% CI 14.9 to 29.2
  • 100 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Mean difference (final values): 18.2 · 95% CI 11.1 to 25.4
SecondaryPercentage of Participants With a Migraine on the Day After Dosing

The percentage of participants with a migraine on the day after dosing, where Day 0 is treatment Day and Day 1 is the day after dosing.

Time frame:
Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With a Migraine on the Day After Dosing
Percentage of participants300 mg ALD403100 mg ALD403Placebo
Percentage of Participants With a Migraine on the Day After Dosing27.828.642.3
Statistical analysis
  • 300 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
  • 100 mg ALD403 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryChange in Monthly Acute Medication Days

An acute medication migraine day was a day with any triptan or ergotamine use as recorded in the eDiary.

Time frame:
Week 1-12
Reported as:
Mean · Acute Medication Migraine Days
Change in Monthly Acute Medication Days
Acute Medication Migraine Days300 mg ALD403100 mg ALD403Placebo
Change in Monthly Acute Medication Days-3.5 ± 4.62-3.3 ± 4.89-1.9 ± 4.18
Statistical analysis
  • 300 mg ALD403 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -1.38 · 95% CI -1.88 to -0.87
  • 100 mg ALD403 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -1.15 · 95% CI -1.66 to -0.65
SecondaryChange From Baseline of Headache Impact Test (HIT-6) Score

The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact).

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Change From Baseline of Headache Impact Test (HIT-6) Score
score on a scale300 mg ALD403100 mg ALD403Placebo
Change From Baseline of Headache Impact Test (HIT-6) Score-7.3 (-40 to 10)-6.2 (-34 to 10)-4.5 (-32 to 15)
Statistical analysis
  • 300 mg ALD403 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -2.88 · 95% CI -3.91 to -1.84
  • 100 mg ALD403 vs Placebo · ANCOVA · p = 0.0010 · Mean difference (final values): -1.73 · 95% CI -2.76 to -0.70
SecondaryChange in Migraine Prevalence From Baseline to Week 4

The avarage change in percentage of participants with a migraine on any given day during baseline and the equivalent avarage rate over Weeks 1-4.

Time frame:
Baseline to Week 4
Reported as:
Mean · percentage of participants with migraine
Change in Migraine Prevalence From Baseline to Week 4
percentage of participants with migraine300 mg ALD403100 mg ALD403Placebo
Change in Migraine Prevalence From Baseline to Week 4-29.8 (-32.10 to -27.49)-27.1 (-29.35 to -24.78)-18.8 (-21.06 to -16.54)
Statistical analysis
  • 300 mg ALD403 vs Placebo · Repeated Measures Model · p = <0.0001 · Mean difference (final values): -11.00 · 95% CI -14.22 to -7.77
  • 100 mg ALD403 vs Placebo · Repeated Measures Model · p = <0.0001 · Mean difference (final values): -8.26 · 95% CI -11.48 to -5.05
Secondary75% Headache Responder Rate

Participants with an average reduction in headache days of at least 75% over Weeks 1 to 12, as compared with baseline.

Time frame:
Week 1-12
Reported as:
Count of participants · Participants
75% Headache Responder Rate
Participants300 mg ALD403100 mg ALD403Placebo
75% Headache Responder Rate614929
Secondary50% Headache Responder Rate

Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline.

Time frame:
Week 1-12
Reported as:
Count of participants · Participants
50% Headache Responder Rate
Participants300 mg ALD403100 mg ALD403Placebo
50% Headache Responder Rate16915095
Secondary100% Migraine Responder Rate

For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.

Time frame:
Week 1-12
Reported as:
Number · percent of participants
100% Migraine Responder Rate
percent of participants300 mg ALD403100 mg ALD403Placebo
100% Migraine Responder Rate15.110.85.1
Secondary100% Headache Responder Rate

For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.

Time frame:
Week 1-12
Reported as:
Number · Percent of participants
100% Headache Responder Rate
Percent of participants300 mg ALD403100 mg ALD403Placebo
100% Headache Responder Rate3.82.01.5
SecondaryChange From Baseline in Monthly Migraine Days (Weeks 13-24)

Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 13-24.

Time frame:
Week 13-24
Reported as:
Mean · Migraine Days
Change From Baseline in Monthly Migraine Days (Weeks 13-24)
Migraine Days300 mg ALD403100 mg ALD403Placebo
Change From Baseline in Monthly Migraine Days (Weeks 13-24)-9.0 ± 6.72-8.3 ± 7.03-6.4 ± 7.16
SecondaryChange From Baseline in Monthly Headache Days (Weeks 1-12)

Monthly headache days are summarized in 28-day intervals, and averaged across Weeks 1-12.

Time frame:
Week 1-12
Reported as:
Mean · Headache Days
Change From Baseline in Monthly Headache Days (Weeks 1-12)
Headache Days300 mg ALD403100 mg ALD403Placebo
Change From Baseline in Monthly Headache Days (Weeks 1-12)-8.8 ± 6.10-8.2 ± 5.78-6.4 ± 5.99
SecondaryTime to First Migraine After Dosing

The time to first migraine after dosing based upon the migraine data entered into the eDiary

Time frame:
32 weeks
Reported as:
Median · days
Time to First Migraine After Dosing
days300 mg ALD403100 mg ALD403Placebo
Time to First Migraine After Dosing4.0 (1.0 to 11.0)4.0 (1.0 to 9.0)2.0 (1.0 to 5.0)
SecondaryChange From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication

The percentage of migraines with acute medication usage. Participants with no migraine will be included with a rate of zero.

Time frame:
Week 1-12
Reported as:
Mean · percentage of acute medication migraines
Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication
percentage of acute medication migraines300 mg ALD403100 mg ALD403Placebo
Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication-14.10 ± 28.86-9.79 ± 26.78-2.82 ± 20.94
SecondaryChange From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication

The percentage of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.

Time frame:
Week 1-12
Reported as:
Mean · percentage of acute medication headaches
Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication
percentage of acute medication headaches300 mg ALD403100 mg ALD403Placebo
Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication-7.46 ± 23.32-3.08 ± 21.31-0.16 ± 19.12
SecondaryPercent Change in Frequency of Migraine Days - Week 1-12

The percent change in frequency of migraine days from Weeks 1-12 was calculated as the number of migraine days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of migraine days over Weeks 1-12.

Time frame:
Week 1-12
Reported as:
Mean · percent change of migraine days
Percent Change in Frequency of Migraine Days - Week 1-12
percent change of migraine days300 mg ALD403100 mg ALD403Placebo
Percent Change in Frequency of Migraine Days - Week 1-12-53.5 ± 35.46-48.6 ± 36.60-34.5 ± 38.17
SecondaryPercent Change in Frequency of Headache Days - Week 1-12

The percent change in frequency of headache days from Weeks 1-12 was calculated as the number of headache days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of headache days over Weeks 1-12.

Time frame:
Week 1-12
Reported as:
Mean · percent change of headache days
Percent Change in Frequency of Headache Days - Week 1-12
percent change of headache days300 mg ALD403100 mg ALD403Placebo
Percent Change in Frequency of Headache Days - Week 1-12-44.1 ± 30.59-41.2 ± 29.20-31.4 ± 28.62
SecondaryChange From Baseline in Percentage of Severe Migraines

The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12.

Time frame:
Week 1-12
Reported as:
Mean · percentage of migraines scored "severe"
Change From Baseline in Percentage of Severe Migraines
percentage of migraines scored "severe"300 mg ALD403100 mg ALD403Placebo
Change From Baseline in Percentage of Severe Migraines-18.17 ± 27.90-16.39 ± 26.17-10.82 ± 25.73
SecondaryChange From Baseline in Percentage of Severe Headache

The change from baseline in percentage of headaches that are classified as severe over Weeks 1-12.

Time frame:
Week 1-12
Reported as:
Mean · percentage of headaches scored "severe"
Change From Baseline in Percentage of Severe Headache
percentage of headaches scored "severe"300 mg ALD403100 mg ALD403Placebo
Change From Baseline in Percentage of Severe Headache-14.00 ± 22.50-14.01 ± 20.95-9.12 ± 22.12
SecondaryChange From Baseline in Monthly Migraine Hours, Weeks 1-12

Migraine hours are the sum of migraines within 4 week intervals, and the average 4 week duration within 12 weeks.

Time frame:
Week 1-12
Reported as:
Mean · migraine hours
Change From Baseline in Monthly Migraine Hours, Weeks 1-12
migraine hours300 mg ALD403100 mg ALD403Placebo
Change From Baseline in Monthly Migraine Hours, Weeks 1-12-80.9 ± 89.17-75.2 ± 90.40-52.8 ± 101.82
SecondaryChange From Baseline in Monthly Headache Hours, Weeks 1-12

Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.

Time frame:
Week 1-12
Reported as:
Mean · headache hours
Change From Baseline in Monthly Headache Hours, Weeks 1-12
headache hours300 mg ALD403100 mg ALD403Placebo
Change From Baseline in Monthly Headache Hours, Weeks 1-12-82.5 ± 88.85-74.6 ± 84.57-54.8 ± 97.15
SecondaryDuration of Migraine-Free Intervals

The number of participants with migraine-free intervals starting within the first 2 weeks of treatment. The longest migraine free interval for each participant is recorded.

Time frame:
32 weeks
Reported as:
Count of participants · Participants
Duration of Migraine-Free Intervals
Participants300 mg ALD403100 mg ALD403Placebo
<= 7 days132146226
8-14 days869575
15-21 days384223
>21 days947342
SecondaryChange From Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores

The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks. All scales are on a range of 0 to 100, with 0 being the worst and 100 being the best. Scales are reported separately. Increases from baseline indicate improvement.

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Change From Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores
score on a scale300 mg ALD403100 mg ALD403Placebo
Physical Functioning3.3 ± 6.222.6 ± 5.981.5 ± 6.88
Role Physical6.0 ± 8.464.6 ± 8.533.6 ± 8.08
Bodily Pain6.2 ± 8.715.1 ± 9.124.0 ± 8.55
General Health3.5 ± 7.452.3 ± 6.890.7 ± 7.53
Vitality4.5 ± 9.024.2 ± 8.842.3 ± 8.23
SecondaryPatient Global Impression of Change (PGIC) at Week 12

The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) at Week 12
Participants300 mg ALD403100 mg ALD403Placebo
Very Much Improved735438
Much Improved14212692
Minimally Improved688285
No Change5169111
Minimally Worse31016
Much Worse021
Very Much Worse010
SecondaryHealth Related Quality of Life (EQ-5D-5L) at Week 12

The EQ-5D-5L is a descriptive system of health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Health Related Quality of Life (EQ-5D-5L) at Week 12
Participants300 mg ALD403100 mg ALD403Placebo
Mobility — No problems289289298
Mobility — Slight Problems414137
Mobility — Moderate Problems8136
Mobility — Severe Problems012
Mobility — Extreme Problems000
Self-care — No problems320337331
Self-care — Slight Problems1367
Self-care — Moderate Problems514
Self-care — Severe Problems001
Self-care — Extreme Problems000
Usual Activities — No problems227233241
Usual Activities — Slight Problems797871
Usual Activities — Moderate Problems272826
Usual Activities — Severe Problems554
Usual Activities — Extreme Problems001
Pain/Discomfort — No problems122121130
Pain/Discomfort — Slight Problems140127120
Pain/Discomfort — Moderate Problems567875
Pain/Discomfort — Severe Problems181416
Pain/Discomfort — Extreme Problems242
Anxiety/Depression — No problems220227219
Anxiety/Depression — Slight Problems918791
Anxiety/Depression — Moderate Problems232527
Anxiety/Depression — Severe Problems455
Anxiety/Depression — Extreme Problems001

Adverse events

Collected over Baseline to Week 32 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
300 mg ALD4030/350 (0%)4/350 (1.1%)52/350 (14.9%)
100 mg ALD4030/356 (0%)3/356 (0.8%)34/356 (9.6%)
Placebo0/366 (0%)3/366 (0.8%)42/366 (11.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
Event300 mg ALD403100 mg ALD403Placebo
GastroenteritisInfections and infestations1/3500/3560/366
FallInjury, poisoning and procedural complications1/3500/3560/366
Spinal Compression FractureInjury, poisoning and procedural complications1/3500/3560/366
Migraine With AuraNervous system disorders1/3500/3560/366
SeizureNervous system disorders1/3500/3560/366
Suicide AttemptPsychiatric disorders1/3500/3560/366
Gastric UlcerGastrointestinal disorders0/3501/3560/366
HaematemesisGastrointestinal disorders0/3501/3560/366
Tibia FractureInjury, poisoning and procedural complications0/3501/3560/366
MigraineNervous system disorders0/3501/3560/366
Most frequent other events
Most frequent other events
Event300 mg ALD403100 mg ALD403Placebo
NasopharyngitisInfections and infestations33/35019/35622/366
Upper respiratory tract infectionInfections and infestations19/35015/35620/366

Baseline characteristics

Safety population includes all participants who received study drug or placebo.

Age, Continuous
Age, Continuous(years)300 mg ALD403100 mg ALD403PlaceboTotal
Mean41.0 ± 10.3641.0 ± 11.7239.6 ± 11.2840.5 ± 11.15
Sex: Female, Male
Sex: Female, Male(Participants)300 mg ALD403100 mg ALD403PlaceboTotal
Female314307325946
Male364941126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)300 mg ALD403100 mg ALD403PlaceboTotal
Hispanic or Latino18333586
Not Hispanic or Latino332323331986
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)300 mg ALD403100 mg ALD403PlaceboTotal
American Indian or Alaska Native1113
Asian1113
Native Hawaiian or Other Pacific Islander1001
Black or African American23213882
White322332321975
More than one race2147
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)300 mg ALD403100 mg ALD403PlaceboTotal
Hungary35311
United States195198232625
Czechia127827
Ukraine344333110
United Kingdom3429
Spain18221858
Russia32272786
Belgium0011
Denmark3216
Italy73515
Georgia36382397
Slovakia45817
Germany32510
Baseline Migraine Days
Baseline Migraine Days(Participants)300 mg ALD403100 mg ALD403PlaceboTotal
Less than 17 days per month197199206602
Greater than or equal to 17 days per month153157160470
Medication overuse headache diagnosis
Medication overuse headache diagnosis(Participants)300 mg ALD403100 mg ALD403PlaceboTotal
No203217221641
Yes147139145431
08

Study locations

145 sites
  • Research Site
    Birmingham, Alabama 35235, United States
  • Research Site
    Phoenix, Arizona 85032, United States
  • Research Site
    Little Rock, Arkansas 72211, United States
  • Research Site
    Carlsbad, California 92011, United States
  • Research Site
    Oceanside, California 92056, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Oxnard, California 93030, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    Redlands, California 92374, United States
  • Research Site
    San Diego, California 92108, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Colorado Springs, Colorado 80918, United States
  • Research Site
    New London, Connecticut 06320, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Miami, Florida 33155, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Tampa, Florida 33606, United States
  • Research Site
    West Palm Beach, Florida 33407, United States
  • Research Site
    Winter Haven, Florida 33880, United States
  • Research Site
    Atlanta, Georgia 30328, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Decatur, Georgia 30030, United States
  • Research Site
    Champaign, Illinois 61820, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Chicago, Illinois 60642, United States
  • Research Site
    Anderson, Indiana 46011, United States
  • Research Site
    Des Moines, Iowa 50309, United States
  • Research Site
    Overland Park, Kansas 66212, United States
  • Research Site
    Prairie Village, Kansas 66208, United States
  • Research Site
    Wichita, Kansas 67207, United States
  • Research Site
    Marrero, Louisiana 70072, United States
  • Research Site
    Waldorf, Maryland 20603, United States
  • Research Site
    Boston, Massachusetts 02135, United States
  • Research Site
    North Attleboro, Massachusetts 02740, United States
  • Research Site
    Watertown, Massachusetts 02472, United States
  • Research Site
    Ann Arbor, Michigan 48104, United States
  • Research Site
    Minneapolis, Minnesota 55402, United States
  • Research Site
    Flowood, Mississippi 39232, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Saint Peters, Missouri 63303, United States
  • Research Site
    Springfield, Missouri 65810, United States
  • Research Site
    Las Vegas, Nevada 89113, United States
  • Research Site
    Lebanon, New Hampshire 03756, United States
  • Research Site
    Princeton, New Jersey 08540, United States
  • Research Site
    Albuquerque, New Mexico 87102, United States
  • Research Site
    Amherst, New York 14226, United States
  • Research Site
    Brooklyn, New York 11229, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10019, United States
  • Research Site
    Plainview, New York 11803, United States
  • Research Site
    Rochester, New York 14609, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    High Point, North Carolina 27262, United States
  • Research Site
    Canton, Ohio 44718, United States
  • Research Site
    Dayton, Ohio 45432, United States
  • Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Research Site
    Scottdale, Pennsylvania 15683, United States
  • Research Site
    Smithfield, Pennsylvania 15478, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Chattanooga, Tennessee 37421, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Dallas, Texas 75214, United States
  • Research Site
    Houston, Texas 77058, United States
  • Research Site
    Houston, Texas 77081, United States
  • Research Site
    North Richland Hills, Texas 76180, United States
  • Research Site
    San Antonio, Texas 78258, United States
  • Research Site
    Salt Lake City, Utah 84109, United States
  • Research Site
    Salt Lake City, Utah 84123, United States
  • Research Site
    Richmond, Virginia 23294, United States
  • Research Site
    Bellevue, Washington 98007, United States
  • Research Site
    Spokane, Washington 99202, United States
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Liege, 4000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Brno, 61500, Czechia
  • Research Site
    Choceň, 565 01, Czechia
  • Research Site
    Prague, 18200, Czechia
  • Research Site
    Praha, 100 34, Czechia
  • Research Site
    Glostrup, 2600, Denmark
  • Research Site
    Viborg, 8800, Denmark
  • Research Site
    Tbilisi, 0112, Georgia
  • Research Site
    Tbilisi, 0160, Georgia
  • Research Site
    Tbilisi, 0179, Georgia
  • Research Site
    Tbilisi, 0186, Georgia
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Nordheim, 45122, Germany
  • Research Site
    Unterhaching, 82008, Germany
  • Research Site
    Budapest, 1033, Hungary
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1145, Hungary
  • Research Site
    Pecs, 7623, Hungary
  • Research Site
    Ancona, 60020, Italy
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Napoli, 80131, Italy

Showing the first 100 of 145 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pozo-Rosich P, Dodick DW, Ettrup A, Hirman J, Cady R. Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies. BMC Neurol. 2022 Oct 25;22(1):394. doi: 10.1186/s12883-022-02914-9. PubMed 36284281 ↗
  • Cowan RP, Marmura MJ, Diener HC, Starling AJ, Schim J, Hirman J, Brevig T, Cady R. Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study. J Headache Pain. 2022 Sep 6;23(1):115. doi: 10.1186/s10194-022-01482-0. PubMed 36068494 ↗
  • Apelian R, Boyle L, Hirman J, Asher D. Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2. J Headache Pain. 2022 Apr 18;23(1):48. doi: 10.1186/s10194-022-01418-8. PubMed 35436857 ↗
  • McAllister P, Kudrow D, Cady R, Hirman J, Ettrup A. Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. Cephalalgia. 2022 Sep;42(10):1005-1012. doi: 10.1177/03331024221089567. Epub 2022 Mar 25. PubMed 35332807 ↗
  • Ashina M, McAllister P, Cady R, Hirman J, Ettrup A. Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2. Cephalalgia. 2022 Jul;42(8):696-704. doi: 10.1177/03331024221077646. Epub 2022 Mar 18. PubMed 35302389 ↗
  • Buse DC, Winner PK, Charleston L 4th, Hirman J, Cady R, Brevig T. Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine. J Headache Pain. 2022 Feb 21;23(1):29. doi: 10.1186/s10194-022-01387-y. PubMed 35189811 ↗
  • Martin V, Nagy AJ, Janelidze M, Giorgadze G, Hirman J, Cady R, Mehta L, Buse DC. Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2. Clin Ther. 2022 Mar;44(3):389-402. doi: 10.1016/j.clinthera.2022.01.006. Epub 2022 Feb 5. PubMed 35131090 ↗
  • Lipton RB, Charleston L 4th, Tassorelli C, Brevig T, Hirman J, Cady R. Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a >/= 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials. J Headache Pain. 2022 Feb 7;23(1):23. doi: 10.1186/s10194-022-01386-z. PubMed 35130836 ↗
  • Smith TR, Spierings ELH, Cady R, Hirman J, Ettrup A, Shen V. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. J Headache Pain. 2021 Nov 25;22(1):143. doi: 10.1186/s10194-021-01360-1. PubMed 34823467 ↗
  • Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021 Mar 30;22(1):16. doi: 10.1186/s10194-021-01227-5. Erratum In: J Headache Pain. 2021 May 25;22(1):46. doi: 10.1186/s10194-021-01253-3. PubMed 33781209 ↗
  • Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020 Oct 6;21(1):120. doi: 10.1186/s10194-020-01186-3. PubMed 33023473 ↗
  • Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020 Mar 31;94(13):e1365-e1377. doi: 10.1212/WNL.0000000000009169. Epub 2020 Mar 24. Erratum In: Neurology. 2023 Aug 8;101(6):283. doi: 10.1212/WNL.0000000000207168. PubMed 32209650 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Nov 2017, 12 months.

Results were first posted in Jun 2020, 2 years 7 months after primary completion. A results delay was requested in Sep 2018.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 12 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2016
First posted
Nov 28, 2016
StartActual
Nov 2016
Primary completionActual
Nov 2017
CompletionActual
Apr 2018
Results delay requested
Sep 17, 2018
Results first posted
Jun 9, 2020
Last update
Jun 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02974153
Responsible party
Sponsor
First posted
Nov 28, 2016
Start date
Nov 2016
Primary completion
Nov 2017
Completion
Apr 2018
Results posted
Jun 9, 2020
Last update
Jun 9, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion